With the announced sale of its Acute Care, Interventional Urology and OEM businesses, Teleflex is entering its next phase as a more focused, higher-growth organization. The acquisition and integration of the Vascular Intervention business, particularly the former BIOTRONIK assets, is a significant driver, with management anticipating the combined Interventional business to generate over $800 million in annual revenues.
Cyborg Score Rationale
In early January 2026, Teleflex announced leadership changes and lowered its preliminary 2025 revenue guidance to about US$3.27 billion due to softer demand and order delays. The reduction in revenue is principally the result of softer than expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia at year end and delays in certain purchase orders in the OEM business, with lower overall order volumes across certain portfolio segments falling short of expectations. The portfolio transformation presents opportunity but execution risk remains elevated.
Top Insights
Stuart Randle appointed Interim President and Chief Executive Officer on January 8, 2026, succeeding Liam Kelly.
Announced portfolio separation plans with Urology, Acute Care, and OEM businesses forming NewCo while RemainCo focuses on vascular access, interventional, and surgical segments.
Teleflex's January 2026 update trimmed 2025 revenue expectations to about US$3.27 billion, citing softer intra aortic balloon pump and catheter demand plus OEM order delays.
Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
Named Competitors
Boston Scientific — Interventional and vascular medical devices
Edwards Lifesciences — Cardiac and vascular devices
Medtronic — Diversified medical device portfolio
B. Braun — Medical devices and infusion therapy
Recent Developments
(January 2026) CEO transition with Stuart Randle appointed Interim President and CEO; Liam Kelly departed; Dr. Stephen Klasko named Chairman
(January 2026) 2025 revenue guidance reduced to approximately $3.27 billion due to softer IABP/catheter demand and OEM order delays
(December 2025) Strategic portfolio restructuring announced with sale of Acute Care, Interventional Urology, and OEM businesses planned
Open the full interactive Teleflex Incorporated report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.